Navigation Links
Study opens new prospects for developing new targeted therapies for breast cancer
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.

The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

This current study was led by Dr Martine Piccart, Director of Medicine at the Jules Bordet Institute in Brussels, and Dr Jose Baselga, Associate Director at Memorial Sloan-Kettering Cancer Center, New York.

The researchers used modern sequencing technology to characterise the genetic aberrations of cancer genes present in tumour samples from a well-defined cohort of advanced postmenopausal patients who were enrolled in the BOLERO-2 clinical trial.

"The results of this study generated hypotheses for developing more rational targeted therapy combinations based on the specific genetic aberrations present in each individual tumour," Dr Piccart said.

"This work, together with previous works published last year, highlights again the genetic heterogeneity of breast cancer. These results show that tumours that may look very similar at the clinical level, can be genetically very different, suggesting that they may require different treatment strategies."

"There is still a long way to go before we will be able to offer truly personalised therapies to cancer patients, and support for research such as this will be critical to accelerate this process," Dr Piccart said.

The study involved postmenopausal women with advanced breast cancer that was hormone receptor positive and HER2 negative taking part in the BOLERO-2 phase III trial. The trial showed that everolimus plus exemestane significantly improved progression-free survival, response rate and clinical benefi
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Law that regulates shark fishery is too liberal: UBC study
3. New study will help protect vulnerable birds from impacts of climate change
4. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
5. BYU study: Using a gun in bear encounters doesnt make you safer
6. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
7. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
8. Crystal structure of archael chromatin clarified in new study
9. EU-funded study underlines importance of Congo Basin for global climate and biodiversity
10. University of Houston study shows BP oil spill hurt marshes, but recovery possible
11. Study demonstrates cells can acquire new functions through transcriptional regulatory network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... or Genetically Modified Organisms, may raise concerns of genes escaping ... But what is the real risk that traits associated ... wild relatives? Interest in plant ecology, crop production and ... University of Nebraska and USDA-ARS to investigate how gene flow ...
... Newport News, Virginia, was walking her employer,s Westie around the ... mysterious blob floating in the water. Co-worker Charlie Schmuck ... by the lake, saw the object, and asked everyone else ... it was "a huge dead snake." Charlie thought it ...
... The rate at which lead poisoning has struck young Rhode ... a Brown University-led geographic analysis of comprehensive health department data ... cases of lead poisoning, researchers have been able to help ... that 12-year period, some census blocks in the state had ...
Cached Biology News:If GMO genes escape, how will the hybrids do? 2If GMO genes escape, how will the hybrids do? 3VIMS scientists help solve mystery of 'alien pod' 2Lead poisoning maps in R.I. reveal huge disparities, guide cleanup 2
(Date:3/3/2015)... 2015 HubCast® Inc. ( http://www.hubcast.com ), ... the expansion of its Global Print Supply Chain with ... the world’s largest cities across 75 countries globally. ... countries providing global enterprises ease, speed, reach, quality, cost ... online order to real-world delivery at postal address around ...
(Date:3/3/2015)... March 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... improving the lives of pets, announced today that it will ... March 12, 2015 after the market close. The Company will ... day. Interested parties may access the call ... 756-4262 internationally, and using conference ID 98449349.  ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research and ... addition of Jain PharmaBiotech,s new report "RNAi - ... , Because of its ability to silence ... been adopted as the research tool to discriminate gene ... RNAi can be designed to target every gene in ...
(Date:3/3/2015)... , March 3, 2015  Synthetic Biologics, Inc. (NYSE ... and diseases, with a focus on protecting the microbiome, announced ... scheduled to present at the 27th Annual ROTH Conference being ... Laguna Niguel in Dana Point, CA. ... March 10, 2015 at 1:00 p.m. (Pacific Time). ...
Breaking Biology Technology:HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... Global Biotechnology Company Adopts Pharsight,s Groundbreaking ... Automation Software, ... ), a leading provider of software and strategic,services for optimizing clinical ... purchased WinNonlin AutoPilot.,This sale marks Pharsight,s third new customer win since ...
... Denosumab is a new drug being,studied to prevent fractures ... phase 3 clinical trial using denosumab were presented,Friday evening ... MD, from the Seattle Cancer Care Alliance., Denosumab ... osteoclasts -- specialized cells that break down bone. Because ...
... Dec. 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX:,MS), ... sclerosis (MS), today,announced that following the meeting of ... has received a recommendation to,continue MAESTRO-01, its pivotal ... of secondary progressive multiple sclerosis., This was ...
Cached Biology Technology:Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer 2Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer 3New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment 2BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2